Novo Nordisk’s Wegovy Pill Delivers a Record Quarter, but the Underlying Picture Is More Complicated

Novo Nordisk's oral Wegovy pill doubles Q1 sales forecasts, but one-time gains mask pricing pressure and looming patent expirations in China and India.

The Danish pharmaceutical giant has kicked off 2026 with a bang, driven by the explosive debut of its oral Wegovy formulation. Yet beneath the headline numbers lies a story of one-time accounting gains, intensifying price pressure, and a race against time in the world’s largest diabetes market.

Nearly 1.3 million prescriptions for the Wegovy pill were written in the first quarter alone, generating revenue of 2.26 billion Danish kroner — double what analysts had penciled in. The oral version now accounts for roughly two-thirds of all new Wegovy prescriptions in the United States, a market share that has surprised even the most bullish forecasters.

On the surface, Novo Nordisk’s numbers look stellar. Revenue climbed 32 percent to 96.8 billion kroner, while operating profit jumped in lockstep. But the headline growth was flattered by a multibillion-kroner reversal of provisions in the US. Stripping out that one-off, currency-adjusted sales actually edged lower, as lower prices ate into volume gains.

Adjusted operating profit still came in at nearly 33 billion kroner, comfortably ahead of market expectations. The star performer was unequivocally the oral Wegovy pill, which has rewritten the launch playbook for obesity treatments.

Cannibalisation Fears Prove Unfounded

Investors had fretted that the pill would eat into sales of the established Wegovy injection. CEO Mike Doustdar has dismissed those concerns, pointing to evidence that patients are using both formulations in tandem. Sales of the injectable version rose 12 percent in parallel, suggesting a synergistic effect rather than cannibalisation.

The competitive landscape remains fierce. US rival Eli Lilly launched its own oral obesity drug, Foundayo, in the spring. Novo Nordisk’s pill has continued to post double-digit growth rates despite the new entrant. But the patent cliff is looming: in countries like India and China, protection for the active ingredient semaglutide is beginning to expire.

A Lifeline in China

China represents both an enormous opportunity and a mounting threat. With an estimated 148 million adults living with diabetes, it is the world’s largest market for glucose-lowering therapies. Novo Nordisk’s base patent for semaglutide expired there in March, but a free-trade agreement with Switzerland has secured regulatory data protection for Ozempic until April 2027.

That breathing room is critical. At least 16 Chinese pharmaceutical companies are developing semaglutide generics, with several already in Phase III trials. In Europe and the US, patent protections extend into the 2030s, but the clock is ticking in emerging markets.

Pipeline Progress and a Buyback Boost

Beyond the obesity franchise, Novo Nordisk is making strides in its broader pipeline. The US Food and Drug Administration approved a high-dose version of Wegovy in March, which achieved an average weight loss of 20.7 percent in clinical trials. The drug hit the US market in April. Separately, the FDA cleared Awiqli, the first weekly basal insulin for type 2 diabetes, giving the company a foothold beyond the fiercely competitive weight-loss space.

To support the share price, management is pressing ahead with a 15 billion kroner share buyback programme. The first tranche has already been completed. The stock currently trades at around €39.33, having rallied nearly 24 percent over the past month. But it remains a long way from its 52-week high of roughly €70, and on a 12-month basis the shares are still down 34 percent.

Price Squeeze and a Cautious Outlook

The diabetes business tells a more sobering story. Currency-adjusted sales in the segment fell 12 percent, with Ozempic revenue down 8 percent and Rybelsus sliding 15 percent. Lower reimbursement rates in the US and an intensifying price war are squeezing margins across the board.

Management has raised its full-year guidance, now forecasting an adjusted revenue decline of between 4 and 12 percent. Analysts at Jefferies noted that the relatively modest adjustment at the lower end of the range could be viewed negatively by the market. The investment bank described the outlook as disappointing, given the strength of the oral Wegovy launch.

What’s Next

The second half of 2026 will be pivotal for Novo Nordisk’s pipeline. The company plans to start the AMAZE-9 study for an oral version of the drug candidate Zenagamtide in the third quarter, followed by a Phase III trial for high-dose Cagrilintide in the fourth quarter.

For now, the Wegovy pill has provided a powerful shot in the arm. But with generics circling in China, price pressure mounting in the US, and a pipeline that still needs to deliver, the Danish drugmaker’s recovery is far from complete.